Antidepressant-induced Paradoxical Anxiety, Akathisia, and Complex Vocal Tics in a Patient with Panic Disorder and Crohn's Disease: A Case Report

被引:0
作者
Koh, Azriel H. K. [1 ]
Loh, Soon Shan [1 ]
Lim, Leslie [1 ]
机构
[1] Singapore Gen Hosp, Dept Psychiat, Outram Rd, Singapore, Singapore
关键词
Antidepressant; fluvoxamine; paradoxical anxiety; akathisia; tics; panic disorder; crohn's disease; IRON; JITTERINESS; ESCITALOPRAM; FLUVOXAMINE; EMERGENCE; SYMPTOMS; RISK;
D O I
10.2174/0115748863270093231114075934
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Antidepressant-induced paradoxical anxiety is a fairly common phenomenon seen in patients who are initiated on antidepressants. However, akathisia is a very uncommon manifestation of antidepressants. Much more rarely, antidepressants are also associated with the emergence of motor and vocal tics. This case adds to the growing literature of rare adverse events induced by antidepressants and aims to stimulate future research into the mechanism and risk factors of this phenomenon.Case Presentation In this case report, we describe a patient with panic disorder and co-morbid Crohn's disease who developed worsening anxiety, akathisia and vocal tics upon initiation of fluvoxamine. This is the first case report to describe the emergence of both akathisia and vocal tics in the same patient following antidepressant initiation. After discontinuation of fluvoxamine, the patient's symptoms resolved.Conclusion Antidepressant-induced akathisia and tics are often distressing both to the patient and their loved ones, and can be very puzzling to the clinician. It is important for clinicians to recognise that, although rare, antidepressants can adverse effects. When these symptoms arise, it should prompt immediate discontinuation of the offending antidepressant.
引用
收藏
页码:478 / 481
页数:4
相关论文
共 38 条
  • [1] Akathisia as an Extrapyramidal Side Effect of Fluoxetine
    Ajufo, Ijeoma
    Basiru, Tajudeen O.
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (06)
  • [2] The emergence of tics during escitalopram and sertraline treatment
    Altindag, A
    Yanik, M
    Asoglu, M
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2005, 20 (03) : 177 - 178
  • [3] [Anonymous], 2022, Diagnostic and Statistical Manual of Mental Disorders, V5th, DOI 10.4324/9780429028267-15
  • [4] World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - Version 3. Part I: Anxiety disorders
    Bandelow, Borwin
    Allgulander, Christer
    Baldwin, David S.
    da Conceicao Costa, Daniel Lucas
    Denys, Damiaan
    Dilbaz, Nesrin
    Domschke, Katharina
    Eriksson, Elias
    Fineberg, Naomi A.
    Hattenschwiler, Josef
    Hollander, Eric
    Kaiya, Hisanobu
    Karavaeva, Tatiana
    Kasper, Siegfried
    Katzman, Martin
    Kim, Yong-Ku
    Inoue, Takeshi
    Lim, Leslie
    Masdrakis, Vasilios
    Menchon, Jose M.
    Miguel, Euripedes C.
    Moller, Hans-Jurgen
    Nardi, Antonio E.
    Pallanti, Stefano
    Perna, Giampaolo
    Rujescu, Dan
    Starcevic, Vladan
    Stein, Dan J.
    Tsai, Shih-Jen
    Van Ameringen, Michael
    Vasileva, Anna
    Wang, Zhen
    Zohar, Joseph
    [J]. WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, 2023, 24 (02) : 79 - 117
  • [5] A Case of Akathisia induced by Escitalopram: Case Report & Review of Literature
    Basu, Bishan
    Gangopadhyay, Tanmoy
    Dutta, Nivedita
    Mandal, Bidyut
    De, Sumitava
    Mondal, Srikrishna
    [J]. CURRENT DRUG SAFETY, 2014, 9 (01) : 56 - 59
  • [6] BROWN KW, 1987, LANCET, V1, P1234
  • [7] David M., 2021, The Maudsley Prescribing Guidelines in Psychiatry, V14th Edition
  • [8] FLUOXETINE AND TICS IN AN ADOLESCENT
    EISENHAUER, G
    JERMAIN, DM
    [J]. ANNALS OF PHARMACOTHERAPY, 1993, 27 (06) : 725 - 726
  • [9] EMERGENCE OF SYMPTOMS OF TOURETTES-SYNDROME DURING FLUVOXAMINE TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER
    FENNIG, S
    FENNIG, SN
    PATO, M
    WEITZMAN, A
    [J]. BRITISH JOURNAL OF PSYCHIATRY, 1994, 164 : 839 - 841
  • [10] Food and Drug Administration, 2004, FDA Public Health Advisory